We believe that a partnership with Allucent, is a significant move forward in bringing our novel PTSD therapeutic to the clinic,” said Silo CEO Eric Weisblum. “With Allucent’s expertise, we believe ...

This NDA submission is an important milestone, and it brings gedatolisib one step closer to becoming available for patients with HR+/HER2- advanced breast cancer,” said Brian Sullivan, CEO and ...

Prescription Drug User Fee Act (PDUFA) goal date set for August 28, 2026 Garching / Munich, Germany, November 13, 2025 – ITM ...

Evotec SE ( EVO) on Wednesday said that it has received a $5 million milestone payment from Bristol Myers Squibb ( BMY ), following the acceptance of an investigational new drug application by the U.S ...

Vasa Therapeutics ("Vasa"), a private, clinical stage biotechnology company developing novel therapies for cardiovascular and ...

Ascletis Pharma announced new preclinical and Phase Ib clinical results for its portfolio of next-generation obesity drug candidates, including ASC36, ASC35, and ASC30, developed using its proprietary ...

Garching / Munich, Germany, November 13, 2025 – (ITM), a leading radiopharmaceutical biotech company, today announced that the U.S. Food and Drug Administration (FDA) completed its filing review and ...

Minnow Inhalerx hopes to be first to market with inhaled synthetic medical cannabis therapies for cancer pain and panic ...

OBI-902, targeting TROP2, gains FDA orphan drug status for cholangiocarcinoma, a rare cancer with poor prognosis and limited treatments. Orphan drug designation provides benefits like tax credits and ...

Lonza helps biotech firms accelerate from DNA to IND with tailored strategies that reduce risk and speed complex biologics to ...

Scientists tested the substance on rats with positive results and are now seeking partnerships with pharmaceutical companies to conduct clinical trials. A research team at the Federal University of AB ...